阿帕替尼联合卡培他滨对晚期转移性三阴性乳腺癌患者临床疗效、无进展生存期及不良反应的影响  

Effect of apatinib combined capecitabine on clinical efficacy,progression free survival and adverse reactions in patients with advanced metastatic triple-negative breast cancer

作　　者：王岩[1] 康艳生 延学学 杨志琴 党东 WANG Yan;KANG Yansheng;YAN Xuexue;YANG Zhiqin;DANG Dong(Department of Pharmacy,the First Hospital of Yulin,Yulin 719000,Shaanxi,China;Department of Pharmacy,the Traditional Chinese Medicine Hospital of Yulin,Yulin 719000,Shaanxi,China;Department of Oncology,the Traditional Chinese Medicine Hospital of Yulin,Yulin 719000,Shaanxi,China)

机构地区：[1]榆林市第一医院药剂科,陕西榆林719000 [2]榆林市中医医院药剂科,陕西榆林719000 [3]榆林市中医医院肿瘤科,陕西榆林719000

出　　处：《癌症进展》2021年第20期2099-2101,2117,共4页Oncology Progress

摘　　要：目的探究阿帕替尼联合卡培他滨对晚期转移性三阴性乳腺癌(TNBC)患者的临床疗效、无进展生存期及不良反应的影响。方法将104例多线治疗失败的晚期TNBC患者按不同的治疗方法分为联合组和对照组,每组52例。联合组口服甲磺酸阿帕替尼和卡培他滨,对照组口服卡培他滨,观察两组患者的无进展生存期(PFS)、临床疗效及不良反应发生情况。结果两组患者均无完全缓解(CR),联合组患者客观缓解率(ORR)为53.85%(28/52)、疾病控制率(DCR)为84.62%(44/52),均明显高于对照组的25.00%(13/52)、51.92%(27/52),差异均有统计学意义(χ^(2)=8.993、12.828,P﹤0.01)。两组患者各不良反应发生率比较,差异均无统计学意义(P﹥0.05)。联合组患者的PFS为6.00个月(95%CI:4.922~7.085),明显长于对照组的4.00个月(95%CI:3.109~5.244),差异有统计学意义(χ^(2)=8.358,P=0.004)。结论阿帕替尼联合卡培他滨治疗TNBC,可有效延长患者的PFS,疗效较好,且不良反应未明显增加,患者耐受性较好。Objective To investigate the effect of apatinib combined capecitabine on clinical efficacy,progression free survival and adverse reactions in patients with advanced metastatic triple-negative breast cancer(TNBC).Method A total of 104 patients with advanced TNBC after failure of multi-line treatments were divided into combined group(n=52,treated with apatinib mesylate tablets+capecitabine)and control group(n=52,treated with capecitabine)according to different treatment methods.The progression free survival(PFS),clinical efficacy and adverse reactions of the two groups were observed.Result There was no complete remission(CR)in the two groups,the objective response rate(ORR)and disease control rate(DCR)of the combined group were 53.85%(28/52)and 84.62%(44/52),which were significantly higher than 25.00%(13/52)and 51.92%(27/52)of the control group(χ^(2)=8.993,12.828,P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The PFS of the combined group was 6.00 months(95%CI:4.922-7.085),which was significantly longer than 4 months(95%CI:3.109-5.244)of the control group(χ^(2)=8.358,P=0.004).Conclusion Alpatinib+capecitabine can effectively prolong the PFS of patients with TNBC.The curative effect is significant,the adverse reactions are not significantly increased,and the patients have good tolerance.

关 键 词：阿帕替尼 三阴性乳腺癌 客观缓解率 无进展生存期 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]